Description
Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment.
Kalorama Information’s Congestive Heart Failure, Major World Markets series looks at CHF treatment. Volume I of this series looks at Pharmaceutical Treatments in the following key categories which are used to treat this disease:
- ACEIs/ARBs
- Beta-Blockers
- Diuretics
- Inotropes
- Vasodilators
- Aldosterone Inhibitors
This Kalorama Information report includes current market, market forecasts, product discussion and pipeline analysis are included for each segement of this report. General trends in this important disease category are also included. Relevant companies in the industry are profiled. This report is the result of Dr. Kenneth Krul’s exhaustive analysis and primary research with key executives in the industry.
- Abbott Laboratories
- Actelion Pharmaceuticals US
- Aldagen
- Alexion Pharmaceuticals
- AstraZeneca LP
- Bayer Healthcare Pharmaceuticals
(Bayer Schering Pharma) - Bristol-Myers Squibb
- CardioVascular Biotherapeutics
- CoGenesys, Inc.
- Encysive Pharmaceuticals
- GlaxoSmithKline (US)
- Inotek Pharmaceuticals
- Mylan Pharmaceuticals
- Novartis Pharmaceutical Corp.
- Pfizer, Inc.
- Roche Pharmaceuticals
- Sanofi-Aventis (US)
- Scios, Inc.
- Vasogen, Inc.
- Zealand Pharma